FOSL1 and breast carcinoma: Psoralen has been discovered to display antiproliferative effects on breast cancer cells due to its ability to increase the expression of Axin2 and decrease the expression of FOSL1, suggesting that psoralen’s mechanism of action in breast cancer involves the regulation of the cell cycle by modulating the expression of Axin2 and FOSL1 [72].